CLAIMS

What is claimed is:

1. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of an autoimmune disorder in a subject in need thereof, wherein a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein is to be administered to the subject, wherein the pharmaceutically effective amount of the ILT7-binding protein is from about 100-350 mg.

2. The use of claim 1, wherein the autoimmune disease is selected from the group consisting of discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE), lupus nephritis, Dermatomyositis, Anti-Synthetase Inflammatory Myositis, and alopecia areata.

3. The use of claim 1, wherein the administration is effective in reducing:

a) a level of plasmacytoid dendritic cells (pDCs) in a tissue of the subject;

b) a type I interferon gene signature (IFNGS); or

c) the level of plasmacytoid dendritic cells (pDCs) in the tissue of the subject and the type I IFNGS, each of each is as compared to a baseline level of the subject before the administration.

4. The use of any one of the preceding claims, wherein the ILT7-binding protein is to be administered with one or more additional therapies.

5. The use of claim 4, wherein the one or more additional therapies comprises a corticosteroid.

6. The use of claim 5, wherein the corticosteroid is prednisone.

7. The use of any one of claims 4-6, wherein the administration of the one or more additional therapies is tapered.

8. The use of claim 1, wherein the pharmaceutically effective amount of the ILT7-binding protein is from about 150-300 mg.

9. The use of claim 8, wherein the pharmaceutically effective amount of the ILT7-binding protein is from about 200-300 mg.

10. The use of any one of the preceding claims, wherein the ILT7-binding protein is to be administered once about every four weeks or once about every twelve weeks.

11. The use of any one of the preceding claims, wherein the pharmaceutically effective amount of the ILT7-binding protein is about 100 mg, 150 mg, 200mg, or 300 mg.

12. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of discoid lupus erythematosus (DLE) in a subject in need thereof, wherein a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein is to be administered to the subject, wherein the pharmaceutically effective amount of the ILT7-binding protein is from about 100 to about 300 mg.

13. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of systemic lupus erythematosus (SLE) in a subject in need thereof, wherein a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein is to be administered to the subject, wherein the pharmaceutically effective amount of the ILT7-binding protein is about 100 mg to about 300 mg.

14. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of lupus nephritis in a subject in need thereof, wherein a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein is to be administered to the subject, wherein the pharmaceutically effective amount of the ILT7-binding protein is about 100 mg to about 300 mg.

15. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of alopecia areata in a subject in need thereof, wherein a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein is to be administered to the subject, wherein the pharmaceutically effective amount of the ILT7-binding protein is about 100 mg to about 300 mg.

16. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of dermatomyositis in a subject in need thereof, wherein a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein is to be administered to the subject.

17. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of Anti-Synthetase Inflammatory Myositis in a subject in need thereof, wherein a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein is to be administered to the subject.

18. The use of any one of claims 16-17, wherein the pharmaceutically effective amount of the ILT7-binding protein is from about 100 mg to about 300 mg.

19. The use of any one of the preceding claims, wherein the ILT7 binding protein is an antibody that comprises heavy chain Complementarity-Determining Regions (HCDRs) HCDR1, HDR2, HCDR3, and light chain Complementarity Determining Regions (LCDRs) LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 3, 4, 5, 6, 7, and 8, respectively.

20. The use of claim 19, wherein the ILT7 binding protein is an antibody comprising a variable heavy chain (VH) that is at least 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:1 and/or a variable light chain (VL) that is at least 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:2.

21. The use of claim 20, wherein the ILT7-binding protein is an antibody comprising a heavy chain variable region (VH) of SEQ ID NO:1 and a light chain variable region (VL) of SEQ ID NO:2.

22. The use of any one of the preceding claims, wherein the ILT7 binding protein is afucosylated.

23. The use of any one of the preceding claims, wherein the ILT7 binding protein comprises a heavy chain comprising SEQ ID NO: 10; and a light chain comprising SEQ ID NO: 9.

24. The use of any one of the preceding claims, wherein the administration is subcutaneous.

25. The use of any one of claims 12-24, wherein the subject is to be administered the ILT7-binding protein every 4 weeks.

26. The use of any one of claims 12-24, wherein the subject is to be administered the ILT7-binding protein every 12 weeks.

27. The use of any one of claims 12-26, wherein prior to the administration, the subject is to be administered at least one initial dose of the ILT7-binding protein.

28. The use of claim 27, wherein the at least one initial dose is to be administered every 2 weeks for 1, 2, 3, 4, 5, or more doses.

29. The use of any one of claims 27-28, wherein the at least one initial dose is about 100-300 mg.

30. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of lupus nephritis in a subject in need thereof, wherein about 100 mg of the ILT7-binding protein is to be administered every 2 weeks for up to 4 weeks followed by 100 mg every 4 weeks thereafter.

31. Use of an immunoglobulin-like transcript 7 (ILT7)-binding protein in the manufacture of a medicament for the treatment of lupus nephritis in a subject in need thereof, wherein about 300 mg of the ILT7-binding protein is to be administered every 2 weeks for up to 4 weeks followed by 300 mg every 12 weeks thereafter.

32. The use of claim 10, wherein the ILT7-binding protein to be administered comprises a first dose, a second dose two weeks after the first dose, and subsequent doses every 4 weeks following the first initial dose.

33. The use of claim 10, wherein the ILT7-binding protein to be administered comprises a first dose, a second dose four weeks after the first dose, and subsequent doses every 12 weeks following the first initial dose.